CEL-SCI Q2 2024 Earnings Report

CEL-SCI EPS Results

• Actual EPS: -$0.14
• Consensus EPS: -$0.14
• Beat/Miss: Met Expectations
• One Year Ago EPS: N/A

CEL-SCI Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

CEL-SCI Announcement Details

• Quarter: Q2 2024
• Date: 5/16/2024
• Time: N/A

CEL-SCI (NYSE:CVM), a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers. It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company's product pipeline includes CEL-2000; CEL-4000; and CEL-5000, which are LEAPS-based product candidates in preclinical trials for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.